A retrospective study on a cohort of 46 patients suffering from Dravet syndrome was carried out to evaluate the long-term efficacy and safety of DIACOMIT® as an add-on therapy to valproate and clobazam. The median follow-up duration was three years.
The study showed a significant reduction of seizure frequency (p<0.001) and duration (p<0.001) as well as a decrease in the number of episodes of status epilepticus (54% decrease in the number of status epilepticus episodes).
This study also showed that Stiripentol’s efficacy was at its best in patients under two years of age. In over twelve years of age patients, the tolerability was decreased.
For references, please access “About DIACOMIT” through the Bibliography part located in Resources tab.